GLP1R and type 2 diabetes mellitus: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have redefined the management of obesity and type 2 diabetes mellitus, producing sustained and clinically meaningful reductions in total body weight alongside significant cardiometabolic benefits.